ALK-Abelló A/S (AKABY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Horsholm, Denmark. 現CEOは Carsten Hellmann.
AKABY を有する IPO日 2013-09-05, 2,566 名の正社員, に上場 Other OTC.
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.